Key Highlights

  • Paysign (NASDAQ:PAYS) ended down 18.94% on November 10, 2026 after revealing that a plasma customer will transfer payment processing for 113 centers to another provider by year-end.
  • Third-quarter Revenue climbed 43% to a record USD 30.8 million, with pharma revenue more than doubling to USD 16.62 million.
  • Over the past 12 months the departing centers generated USD 11.3 million of revenue and USD 5.2 million of gross profit, and the fourth quarter will absorb a revenue hit of about USD 1.5 million.
  • Guidance for 2026 revenue was held at USD 114.0 million to USD 117.0 million, while the profit outlook was raised, including adjusted EBITDA of USD 38.5 million to USD 40.0 million.

A Record Quarter Overshadowed

Two main businesses drive Paysign (NASDAQ:PAYS): prepaid cards used by plasma collection centers to pay donors, and patient affordability programmes through which drug companies provide co-pay assistance. The third quarter was its strongest yet. Revenue rose 42.6% to USD 30.80 million, gross Margin expanded to 64.7% from 56.3%, Operating Margin reached 23.8% and Net Income tripled to USD 6.74 million, or USD 0.11 per diluted share. Adjusted EBITDA more than doubled to USD 10.98 million. Attention nonetheless went to the 113 plasma centers being lost, about a fifth of the network. Plasma has traditionally delivered steady, high-margin revenue, and those centers accounted for USD 11.3 million over the last year, more than a third of what the plasma segment earns annually. In the quarter plasma revenue grew 7.5% to USD 13.83 million, yet the count of centers had already slipped to 562 from 595, and management now sees the year ending with only 445 to 450.

Pharma Carries the Growth

Offsetting that is the pharma segment, up 109.8% in the quarter. Paysign now operates 167 active patient affordability programmes, a net gain of 62 over the last 12 months, and expects 190 to 195 by the end of 2026. Pharmaceutical firms rely on them to make branded medicines affordable, and Demand has grown as co-pay costs climb and insurers tighten coverage. Chief executive Mark Newcomer called patient affordability a compounding business, since each new programme adds recurring revenue. Chief financial officer Jeff Baker noted results came in above the top end of guidance. With USD 34.54 million of cash and no bank debt, the Balance Sheet is clean, and full-year targets were raised for gross margin of 63.5% to 64.5%, net income of USD 23.0 million to USD 24.0 million and Diluted Earnings per Share of USD 0.37 to USD 0.38.

Items to Monitor

The central question is whether losing this plasma Business begins a wider pattern or reflects one customer's choice. Plasma operators have consolidated, and bigger groups may want to standardise payment systems. Canadian investors in Paysign (NASDAQ:PAYS), which can be accessed through Canadian brokerages offering US-listed stocks, will look to 2027 guidance for the size of the plasma revenue gap, the pace of new pharma programmes and margins as the mix shifts. Rapid pharma growth could Fill the lost revenue within a year, but the shares are likely to stay sensitive to further customer news. Another change in customer mix would alter the margin profile. Regulatory changes to co-pay assistance rules would also touch the pharma business.

Where Things Stand

Paysign dropped 18.94% after a customer said it will move 113 plasma centers to another provider, even as third-quarter revenue rose 43% to a record USD 30.8 million and profit guidance went up. The pharma affordability business, growing above 100%, is now the key driver. The size of the 2027 plasma gap and new programme wins will shape how fast the shares recover.